ClinicalTrials.gg
RecruitingNCT05743400PHASAL-GAUpdated Sep 19, 2024

Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation

A Phase 4 interventional study of Thymoglobulin 25 milligrams (mg) Injection and blood test in Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy, sponsored by Hospices Civils de Lyon. Recruiting at 2 sites in France. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Hospices Civils de Lyon · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Graft vs Host Disease with a site in France — 10 open to participants now, 14 under way, 4 of them phase 3. Graft vs Host Disease · France.

Planned enrollment
35th of 47
35 · median 65
Started
2023
with 2 others
Phase 4
3 of 54
1 open now
Primary completion
2025-04
later than 2 of 13 live
Registered
48th of 54
by date

Among the 54 studies in Graft vs Host Disease with a site in France, this one is the 35th largest by planned enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 in phase 4, reaches primary completion later than 2 of the 13 other live ones, and was the 48th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

10 of the 54 studies in Graft vs Host Disease with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Graft vs Host Disease with a site in France, or all of them as a file.
02

Study summary

Thymoglobulin is widely applied as serotherapy in order to prevent acute graft-versus-host disease (GvHD) and graft rejection in patients undergoing non-Human Leukocyte Antigen (HLA)-identical hematopoietic stem cell transplantations (HSCT), with a delicate balance between prevention of GvHD and the promotion of immune reconstitution. Thymoglobulin is known as a drug with high pharmacokinetic (PK) variability. This variability influences drug exposure, which in turn determines the drug response of pharmacodynamics (PD). In order to maintain efficacy while reducing adverse effects of drugs across the entire age range, identification of the PK/PD relationships and the effect of growth and maturation on the different PK and PD parameters involved are crucial.

The investigators hypothesise that a better knowledge of Thymoglobulin PK and its covariates would help to individualise dosage regimen and would improve clinical outcomes, such as GvHD and immune reconstitution.

The investigators aim to build a population PK model of Thymoglobulin in order to study PK variability and its covariates. This model will help in optimizing dosage regimen in an individually way.

03

Conditions studied

  • Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy

Browse trials for

Keywords

  • Hematopoietic stem cell transplantation
  • Pharmacokinetics
  • HSCT
  • Anti-thymocyte globulin
  • Graft versus host disease
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient receiving Thymoglobulin therapy as part of a first
  • Age ≥ 2 years
  • Lansky or score ≥ 50%.
  • Enrolled in a social security plan
  • Patient 18 years of age or older who is informed and has consented to participate in the study or minor patient whose parents/guardians have been informed and have given consent for the minor patient to participate in the study
  • Female patients of must have an effective method of (a pregnancy test will also be performed at inclusion).

Exclusion criteria

Exclusion Criteria:

  • Patient having received serotherapy (Thymoglobulin® or other) within 3 months before this
  • Patient receiving another serotherapy during conditioning (Campath®)
  • Patients with uncontrolled acute or chronic infections for which any form of would be
  • Known to Thymoglobulin®.
  • Pregnant or lactating women
  • Patient participating simultaneously in another study of an drug (no exclusion period)
  • Patient under legal protection or deprived of liberty
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Experimental treatment arm

    Children over two years and adults undergoing a first hematopoietic stem cell transplantation will receiveThymoglobulin® as part of the conditioning.

    Drug: Thymoglobulin 25 milligrams (mg) Injection · Biological: blood test

Interventions

  • DrugThymoglobulin 25 milligrams (mg) Injection

    Patients will receive thymoglobulin between 5 and 20 milligrams/kilograms (mg/kg) as an intravenous infusion over a period of 2 to 5 days depending on the dose and the transplant package chosen by the physician.

  • Biologicalblood test

    Thymoglobulin® serum levels Time frame : samples will be drawn at the following points : * 1 after each end of perfusion ; * 1 though concentration before each perfusion ; * 3 blood samples in 3 different days during the first week; * 1 weekly for 2 weeks post HSCT.

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC)

    Measure of the Thymoglobulin® exposure by the PK criteria : Area under the concentration-time curve (AUC) . AUC is measured by day since the first day of Thymoglobulin infusion during conditioning (day 0) until elimination tf the drug. AUC is expressed as milligrams/hour/Liter. (mg/h/L)

    Time frame: until elimination tf the drug (maximum 3 weeks post hematopoietic stem cell transplantation)

Secondary outcomes

  1. Objective function value (OFV)

    Comparison of the OFV of different build population pharmacokinetic models based on results of pharmacokinetic analysis, from start of thymoglobulin® infusion until elimination of the drug

    Time frame: until elimination tf the drug (maximum 3 weeks post hematopoietic stem cell transplantation)

  2. Coefficient of variation of AUC

    Ratio of typical variation of AUC to the mean AUC. AUC is measured by day since the first day of Thymoglobulin infusion during conditioning (day 0) until elimination of the drug

    Time frame: until elimination tf the drug (maximum 3 weeks post hematopoietic stem cell transplantation)

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Apr 2025, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Feb 24, 2023
StartActual
Sep 25, 2023
Primary completionEst.
Apr 25, 2025
CompletionEst.
Apr 25, 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05743400
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Sep 25, 2023
Primary completion
Apr 25, 2025 (estimated)
Completion
Apr 25, 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Michael Philippe, MD, PhD
Contact
michael.philippe@lyon.unicancer.fr
0469166595 ext. +33
Sylvain Goutelle, PU, PH
Contact
sylvain.goutelle@chu-lyon.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion